Compare · GILD vs MGX
GILD vs MGX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 6111.4x MGX ($31.9M).
- Over the past year, GILD is up 27.2% and MGX is down 73.9% - GILD leads by 101.1 points.
- GILD has been more active in the news (6 items in the past 4 weeks vs 2 for MGX).
- GILD has more recent analyst coverage (25 ratings vs 9 for MGX).
- Company
- Gilead Sciences Inc.
- Metagenomi Therapeutics Inc.
- Price
- $156.22-0.76%
- $0.80-6.18%
- Market cap
- $195.13B
- $31.9M
- 1M return
- +3.48%
- -30.04%
- 1Y return
- +27.19%
- -73.94%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2024
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 9
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
Latest MGX
- Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
- Metagenomi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Reid Laurence bought $23,401 worth of shares (20,000 units at $1.17) (SEC Form 4)
- Officer Wein Matthew sold $415 worth of shares (358 units at $1.16), decreasing direct ownership by 0.28% to 126,133 units (SEC Form 4) (withholding tax)
- Officer Irish Jian sold $2,479 worth of shares (2,140 units at $1.16), decreasing direct ownership by 0.57% to 375,393 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Wapnick Pamela sold $2,214 worth of shares (1,911 units at $1.16), decreasing direct ownership by 0.92% to 206,580 units (SEC Form 4) (for withholding tax)
- Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
- SEC Form 10-Q filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results